Press Releases

Date Title and Summary Additional Formats
Toggle Summary Conatus Pharmaceuticals Inc. Announces Pricing of Initial Public Offering
SAN DIEGO, July 25, 2013 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (Nasdaq:CNAT), a biotechnology company focused on the development and commercialization of novel medicines to treat liver disease, today announced the pricing of its initial public offering of 6,000,000 shares of its common
View HTML
Toggle Summary Conatus Pharmaceuticals Inc. Files Registration Statement for Proposed Initial Public Offering
SAN DIEGO, June 14, 2013 —Conatus Pharmaceuticals Inc. today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to the proposed initial public offering of its common stock.
View HTML